Patients with stage III CRC and positive expression of epidermal growth factor receptor (EGFR) have worse prognoses [16] and may require additional agents to enhance the efficacy of fluoropyrimidine-based chemotherapy. Here, EGFR is linked to colorectal carcinoma.